TREA

88049205 - ACTIMED THERAPEUTICS

Follow

Information

  • Trademark
  • 88049205
  • Serial Number
    88049205
  • Registration Number
    6734037
  • Filing Date
    July 23, 2018
    5 years ago
  • Registration Date
    May 24, 2022
    2 years ago
  • Transaction Date
    May 25, 2022
    2 years ago
  • Status Date
    May 24, 2022
    2 years ago
  • Published for Opposition Date
    March 08, 2022
    2 years ago
  • Location Date
    May 24, 2022
    2 years ago
  • Status Code
    700
  • Current Location
    PUBLICATION AND ISSUE SECTION
    Employee Name
    CORWIN, KEVIN SCOTT
  • Attorney Docket Number
    0265002
    Attorney Name
    M. Scott Alprin
    Law Office Assigned Location Code
    M30
  • Owners
Information
Mark Drawing Code
4000
Mark Identification
ACTIMED THERAPEUTICS
Case File Statements
  • GS0051: Pharmaceutical, medical and therapeutic substances and preparations; pharmaceutical, medical and therapeutic substances and preparations for the treatment and management of severe or chronic illnesses and diseases; pharmaceutical, medical and therapeutic substances and preparations for countering adverse effects of cancers, and of severe or chronic illnesses and diseases; pharmaceutical, medical and therapeutic substances and preparations for treatment and management of physical function; pharmaceutical, medical and therapeutic substances and preparations for treatment and prevention of muscle wasting; pharmaceutical, medical and therapeutic substances and preparations for treatment and management of patient tolerance of therapies, in particular anticancer therapy; pharmaceutical, medical and therapeutic substances and preparations for the treatment and management of cachexia, in particular cancer cachexia; pharmaceutical, medical and therapeutic substances and preparations for the treatment and management of the side effects of medical treatments, in particular of cancer treatments; pharmaceutical, medical and therapeutic substances and preparations for the treatment and management of severe or chronic illnesses and diseases of the lung; pharmaceutical, medical and therapeutic substances and preparations for the treatment and management of severe or chronic illnesses and diseases of the kidney; pharmaceutical, medical and therapeutic substances and preparations for the treatment and management of severe or chronic illnesses and diseases of the heart; pharmaceutical, medical and therapeutic substances and preparations for the treatment and management of severe or chronic illnesses and diseases of the liver; pharmaceutical, medical and therapeutic substances and preparations for the treatment and management of severe or chronic illnesses and diseases of the brain; pharmaceutical, medical and therapeutic substances and preparations for countering adverse effects of chronic heart failure; pharmaceutical, medical and therapeutic substances and preparations for countering adverse effects of chronic renal failure; pharmaceutical, medical and therapeutic substances and preparations for countering adverse effects of chronic liver failure; pharmaceutical, medical and therapeutic substances and preparations for countering adverse effects of chronic obstructive pulmonary disease; pharmaceutical, medical and therapeutic substances and preparations for countering adverse effects of neurological-muscular disorders
  • GS0441: Information, advisory and consultancy services relating to medicine and healthcare; medical and surgical diagnosis and treatment services; medical analysis and reporting services relating to the treatment of patients; assessment and monitoring of patients; preparation of data and reports relating to medicine and healthcare; medical testing services relating to the diagnosis and treatment of illnesses, diseases and medical conditions; providing information relating to the management, preparation and dispensing of medications; medical, health, dentistry, veterinary and pharmaceutical services; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to severe or chronic illnesses and diseases; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to countering adverse effects of cancers, and of severe or chronic illnesses and diseases; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to physical function and muscle wasting; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to patient tolerance of therapies, in particular anticancer therapy; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to the treatment and management of cachexia, in particular cancer cachexia; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to the treatment and management of the side effects of medical treatments, in particular of cancer treatments; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to the treatment and management of severe or chronic illnesses and diseases of the lung; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to the treatment and management of severe or chronic illnesses and diseases of the kidney; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to the treatment and management of severe or chronic illnesses and diseases of the heart; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to the treatment and management of severe or chronic illnesses and diseases of the liver; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to the treatment and management of severe or chronic illnesses and diseases of the brain; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to countering adverse effects of chronic heart failure; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to countering adverse effects of chronic renal failure; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to countering adverse effects of chronic liver failure; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to countering adverse effects of chronic obstructive pulmonary disease; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to countering adverse effects of neurological-muscular disorders; advisory, information and consultancy services relating to all the aforesaid services
  • D10000: "THERAPEUTICS"
Case File Event Statements
  • 5/24/2022 - 2 years ago
    42 - NOTICE OF REGISTRATION CONFIRMATION EMAILED Type: NRCC
  • 5/24/2022 - 2 years ago
    41 - REGISTERED-PRINCIPAL REGISTER Type: R.PR
  • 3/8/2022 - 2 years ago
    40 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 3/8/2022 - 2 years ago
    39 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 2/16/2022 - 2 years ago
    38 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 1/27/2022 - 2 years ago
    37 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 1/27/2022 - 2 years ago
    36 - EXAMINER'S AMENDMENT ENTERED Type: XAEC
  • 1/27/2022 - 2 years ago
    35 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN
  • 1/27/2022 - 2 years ago
    34 - EXAMINERS AMENDMENT E-MAILED Type: GNEA
  • 1/27/2022 - 2 years ago
    33 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA
  • 12/16/2021 - 2 years ago
    32 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 12/16/2021 - 2 years ago
    31 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 12/9/2021 - 2 years ago
    30 - TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED Type: ERSI
  • 10/1/2021 - 2 years ago
    29 - NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED Type: GNS2
  • 10/1/2021 - 2 years ago
    28 - INQUIRY TO SUSPENSION E-MAILED Type: GNSI
  • 10/1/2021 - 2 years ago
    27 - SUSPENSION INQUIRY WRITTEN Type: CNSI
  • 9/24/2021 - 2 years ago
    26 - SUSPENSION CHECKED ¿ TO ATTORNEY FOR ACTION Type: RCCK
  • 3/2/2021 - 3 years ago
    25 - REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED Type: RCSC
  • 8/6/2020 - 3 years ago
    24 - NOTIFICATION OF LETTER OF SUSPENSION E-MAILED Type: GNS3
  • 8/6/2020 - 3 years ago
    23 - LETTER OF SUSPENSION E-MAILED Type: GNSL
  • 8/6/2020 - 3 years ago
    22 - SUSPENSION LETTER WRITTEN Type: CNSL
  • 7/17/2020 - 3 years ago
    21 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 7/17/2020 - 3 years ago
    20 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 7/12/2020 - 3 years ago
    19 - ASSIGNED TO LIE Type: ALIE
  • 6/30/2020 - 3 years ago
    18 - TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED Type: ERSI
  • 1/27/2020 - 4 years ago
    17 - NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED Type: GNS2
  • 1/27/2020 - 4 years ago
    16 - INQUIRY TO SUSPENSION E-MAILED Type: GNSI
  • 1/27/2020 - 4 years ago
    15 - SUSPENSION INQUIRY WRITTEN Type: CNSI
  • 7/2/2019 - 4 years ago
    14 - NOTIFICATION OF LETTER OF SUSPENSION E-MAILED Type: GNS3
  • 7/2/2019 - 4 years ago
    13 - LETTER OF SUSPENSION E-MAILED Type: GNSL
  • 7/2/2019 - 4 years ago
    12 - SUSPENSION LETTER WRITTEN Type: CNSL
  • 5/29/2019 - 5 years ago
    11 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 5/28/2019 - 5 years ago
    10 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 5/28/2019 - 5 years ago
    9 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 11/27/2018 - 5 years ago
    8 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN
  • 11/27/2018 - 5 years ago
    7 - NON-FINAL ACTION E-MAILED Type: GNRT
  • 11/27/2018 - 5 years ago
    6 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 11/19/2018 - 5 years ago
    5 - ASSIGNED TO EXAMINER Type: DOCK
  • 11/19/2018 - 5 years ago
    4 - ASSIGNED TO EXAMINER Type: DOCK
  • 11/8/2018 - 5 years ago
    3 - ASSIGNED TO EXAMINER Type: DOCK
  • 7/27/2018 - 5 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM Type: NWOS
  • 7/26/2018 - 5 years ago
    1 - NEW APPLICATION ENTERED IN TRAM Type: NWAP